Kymera Therapeutics, Inc. (KYMR) financial statements and ratios from SEC XBRL: revenue $39.21M (TTM), net margin -794.0%, revenue growth 466.4% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $39.21M |
| Net Margin | -794.0% |
| Revenue Growth (YoY) | 466.4% |
| EPS Growth (YoY) | -34.7% |
| FCF Growth (YoY) | -10.0% |
| Price / Book | 6.69 |
| Price / Sales | 96.22 |
| FCF Yield | -2.4% |
| Altman Z-Score | 35.53 (safe) |
| Sector P/E (Healthcare) | 21.6 |
KYMR overview · KYMR earnings · KYMR KPIs · KYMR investor relations · KYMR ownership · KYMR peers · KYMR filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.